![ELOCTATE® (Antihemophilic Factor Recombinant), Fc Fusion Protein]](/Content/images/eloctate-logo.svg){kind=logo}
Please see full Prescribing Information.
IMPORTANT SAFETY INFORMATION AND INDICATION
IMPORTANT SAFETY INFORMATION
What is the most important information I need to know about ALTUVIIIO?
Do not attempt to give yourself an injection unless you have been taught how by your healthcare provider or hemophilia center. You must carefully follow your healthcare provider's instructions regarding the dose and schedule for injecting ALTUVIIIO so that your treatment will work best for you.
Who should not use ALTUVIIIO?
You should not use ALTUVIIIO if you have had an allergic reaction to it in the past.
What should I tell my healthcare provider before using ALTUVIIIO?
Tell your healthcare provider if you have had any medical problems, take any medications, including prescription and non-prescription medicines, supplements, or herbal medicines, are breastfeeding, or are pregnant or planning to become pregnant.
What are the possible side effects of ALTUVIIIO?
You can have an allergic reaction to ALTUVIIIO. Call your healthcare provider or emergency department right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.
Your body can also make antibodies called "inhibitors" against ALTUVIIIO. This can stop ALTUVIIIO from working properly. Your healthcare provider may give you blood tests to check for inhibitors.
The common side effects of ALTUVIIIO are headache and joint pain.
These are not the only possible side effects of ALTUVIIIO. Tell your healthcare provider about any side effect that bothers you or does not go away.
INDICATION
ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).
Your healthcare provider may give you ALTUVIIIO when you have surgery.
Some see a drummer. We see the nearly 70 joints behind each beat
WHEN UP TO 80% OF BLEEDS OCCUR IN THE JOINTS
YOU NEED BLEED AND JOINT BLEED PROTECTION* YOU CAN COUNT ON
bleeds per year
1.6 median overall bleeds per year†
joint bleeds per year
0 median joint bleeds per year†
target joints resolved
~100% of target joints resolved in adults and adolescents treating with ELOCTATE prophylaxis‡
PRESCRIBED
#1 prescribed
extended half-life
Factor VIII in the US§
Talk to your doctor to see if ELOCTATE is right for you.
*ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.
†In the A-LONG study, 164 adults and adolescents ages 12-65 received ELOCTATE either every 3 to 5 days, once weekly, or on demand.
‡The ASPIRE extension study included 150 people who completed A-LONG. Data from patients treating prophylactically with ELOCTATE for at least 12 months, who had target joints at enrollment in ASPIRE. 234 out of 235 target joints were resolved. A target joint is defined as a major joint with 3 or more bleeding episodes in a consecutive 6-month period. Target joint resolution is defined as 2 or fewer spontaneous bleeds in a 12-month period.
§#1 prescribed based on HTC reported data as of March 2022.
HELP HUB
Get the resources and support you deserve at every step of your hemophilia journey.
VISIT HUBSEE WHY PEOPLE LIKE YOU CHOOSE ELOCTATE
From reliable, extended half-life treatment to the many resources available, it's no wonder these patients count on ELOCTATE.
Gabriel was empowered by his healthcare team to make the switch to ELOCTATE.
SEE GABRIEL'S STORY >Dosing less often helps Chet's son Caleb focus on basketball.
SEE THEIR STORY >Craig and his doctor chose prophy with ELOCTATE to protect his body and his joints from bleeds after treating on demand for decades.
SEE CRAIG'S STORY >Gabriel was empowered by his healthcare team to make the switch to ELOCTATE.
SEE GABRIEL'S STORY >Dosing less often helps Chet's son Caleb focus on basketball.
SEE THEIR STORY >Craig and his doctor chose prophy with ELOCTATE to protect his body and his joints from bleeds after treating on demand for decades.
SEE CRAIG'S STORY >CONTACT YOUR CoRe
Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options. Use our handy CoRe Locator to find the CoRe team member nearest you.
Get informed. Stay informed.
Let's stay in touch. We'll occasionally send you important information on Hemophilia A and ELOCTATE.
LET'S GET STARTEDELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
IMPORTANT SAFETY INFORMATION AND INDICATION
+
IMPORTANT SAFETY INFORMATION
Do not use ELOCTATE if you have had an allergic reaction to it in the past.
Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies, are breastfeeding, are pregnant or planning to become pregnant, or have been told you have inhibitors (antibodies) to Factor VIII.
Allergic reactions may occur with ELOCTATE. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.
Your body can also make antibodies called "inhibitors" against ELOCTATE, which may stop ELOCTATE from working properly.
Additional common side effects of ELOCTATE are headache, rash, joint pain, muscle pain and general discomfort.
If you have risk factors for developing abnormal blood clots in your body, such as an indwelling venous catheter, treatment with Factor VIII may increase this risk.
These are not all the possible side effects of ELOCTATE. Talk to your healthcare provider right away about any side effect that bothers you or that does not go away, or if bleeding is not controlled after using ELOCTATE.
INDICATION
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
PLEASE SEE FULL PRESCRIBING INFORMATIONMANUFACTURED BY
Bioverativ Therapeutics Inc.
Waltham, MA 02451 USA
U.S. License #2078
CLICK HERE TO LEARN MORE ABOUT SANOFI'S COMMITMENT TO FIGHTING COUNTERFEIT DRUGS.
INDICATION
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
MAT-US-2022223-v8.0-05/2024 LAST UPDATED: MAY 2024